Psyence Biomedical ( (PBM) ) has issued an announcement.
On April 2, 2025, Psyence Biomedical’s subsidiary, Psyence Australia Pty Ltd, entered into a binding letter of intent with Southern Star Research to transition the CRO services for its Phase IIb clinical trial of the psilocybin drug PEX010 from iNGENū to Southern Star Research. This transition involves Southern Star Research providing startup activities to ensure a smooth handover of clinical, regulatory, and operational responsibilities. The previous engagement with iNGENū was formally terminated on April 3, 2025, with an exit deed that includes a 45-day transition support period at no cost. This strategic move is expected to impact Psyence’s operations by potentially enhancing the execution of its clinical trials, thereby strengthening its position in the psychedelic-assisted therapy market.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a company operating in the biotechnology industry, focusing on the development of psychedelic-assisted therapies. Its primary product is a botanical psilocybin drug candidate, PEX010, aimed at treating adjustment disorder in cancer patients.
YTD Price Performance: -78.27%
Average Trading Volume: 366,632
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.16M
For an in-depth examination of PBM stock, go to TipRanks’ Stock Analysis page.